menu
    • menu
    [{"orgOrder":0,"company":"Medivir","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Fostroxacitabine Bralpamide","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medivir","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medivir \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Medivir \/ Not Applicable"},{"orgOrder":0,"company":"Medivir","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Fostroxacitabine Bralpamide","moa":"DNA polymerase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medivir","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medivir \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Medivir \/ Not Applicable"},{"orgOrder":0,"company":"Medivir","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Fostroxacitabine Bralpamide","moa":"DNA polymerase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medivir","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medivir \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Medivir \/ Not Applicable"},{"orgOrder":0,"company":"Medivir","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Fostroxacitabine Bralpamide","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medivir","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medivir \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Medivir \/ Not Applicable"},{"orgOrder":0,"company":"Medivir","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Fostroxacitabine Bralpamide","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medivir","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medivir \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Medivir \/ Not Applicable"},{"orgOrder":0,"company":"Medivir","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Fostroxacitabine Bralpamide","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medivir","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medivir \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Medivir \/ Not Applicable"},{"orgOrder":0,"company":"Medivir","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Fostroxacitabine Bralpamide","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medivir","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medivir \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Medivir \/ Not Applicable"},{"orgOrder":0,"company":"Medivir","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Fostroxacitabine Bralpamide","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medivir","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medivir \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Medivir \/ Not Applicable"},{"orgOrder":0,"company":"Medivir","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Fostroxacitabine Bralpamide","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medivir","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medivir \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Medivir \/ Not Applicable"},{"orgOrder":0,"company":"Medivir","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Fostroxacitabine Bralpamide","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medivir","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medivir \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Medivir \/ Not Applicable"},{"orgOrder":0,"company":"Medivir","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Fostroxacitabine Bralpamide","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medivir","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medivir \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Medivir \/ Not Applicable"},{"orgOrder":0,"company":"Medivir","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Fostroxacitabine Bralpamide","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medivir","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medivir \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Medivir \/ Not Applicable"},{"orgOrder":0,"company":"Medivir","sponsor":"Quotient Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Fostroxacitabine Bralpamide","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medivir","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medivir \/ Quotient Sciences","highestDevelopmentStatusID":"7","companyTruncated":"Medivir \/ Quotient Sciences"},{"orgOrder":0,"company":"Medivir","sponsor":"Hallberg Management AB","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Small molecule","year":"2024","type":"Private Placement","leadProduct":"Fostroxacitabine Bralpamide","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medivir","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Capsule","sponsorNew":"Medivir \/ Hallberg Management AB","highestDevelopmentStatusID":"7","companyTruncated":"Medivir \/ Hallberg Management AB"},{"orgOrder":0,"company":"Medivir","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Fostroxacitabine Bralpamide","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medivir","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medivir \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Medivir \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Fostroxacitabine Bralpamide

    Menu

    Fostroxacitabine Bralpamide

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Medivir

                            Sweden arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Medivir

                            Sweden arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fostroxacitabine Bralpamide,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Hallberg Management AB

                            Deal Size : $12.3 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            Medivir Carries Out a Directed Share Issue of Approx. SEK 20 Million

                            Details : Medivir is focusing on the development of MIV-818 (fostroxacitabine bralpamide), a pro-drug designed to selectively treat hepatocellular carcinoma (HCC).

                            Brand Name : MIV-818

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            January 22, 2024

                            Lead Product(s) : Fostroxacitabine Bralpamide,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Hallberg Management AB

                            Deal Size : $12.3 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Medivir

                            Sweden arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Medivir

                            Sweden arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fostroxacitabine Bralpamide,Lenvatinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Quotient Sciences

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Quotient Sciences Supports Medivir with Updated Formulation of Fostrox

                            Details : MIV-818 (fostroxacitabine bralpamide) is DNA inhibitor. It is being evaluated under phase 1/2 clinical development in combination with Lenvima (lenvatinib) for the treatment of hepatocellular carcinoma.

                            Brand Name : MIV-818

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 27, 2023

                            Lead Product(s) : Fostroxacitabine Bralpamide,Lenvatinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Quotient Sciences

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Medivir

                            Sweden arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Medivir

                            Sweden arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fostroxacitabine Bralpamide

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Medivir Announces Updated Formulation of Fostrox, Critical to Support Planned Study with Accelerated Approval ...

                            Details : Fostrox (fostroxacitabine bralpamide) is an oral nucleotide DNA polymerase inhibitor. It is being developed for the treatment of patients with hepatocellular carcinoma (HCC).

                            Brand Name : Fostrox

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 27, 2023

                            Lead Product(s) : Fostroxacitabine Bralpamide

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Medivir

                            Sweden arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Medivir

                            Sweden arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fostroxacitabine Bralpamide,Lenvatinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Medivir to Report New and Updated Data from Ongoing Phase 2a HCC Study as Part of its Q3 Report on Friday

                            Details : MIV-818 (fostroxacitabine bralpamide) is an orally active troxacitabine-based nucleotide prodrug, which is investigated in with fostrox in combination with Lenvima for the treatment of primary liver cancer.

                            Brand Name : MIV-818

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 25, 2023

                            Lead Product(s) : Fostroxacitabine Bralpamide,Lenvatinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Medivir

                            Sweden arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Medivir

                            Sweden arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fostroxacitabine Bralpamide,Lenvatinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Fostrox + Lenvima Continues to Show Promising Tumor Control in HCC, all Patients Have now Dosed at Least two T...

                            Details : MIV-818 (fostroxacitabine bralpamide) is an orally active troxacitabine-based nucleotide prodrug, which is investigated in with fostrox in combination with Lenvima for the treatment of primary liver cancer.

                            Brand Name : MIV-818

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 05, 2023

                            Lead Product(s) : Fostroxacitabine Bralpamide,Lenvatinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Medivir

                            Sweden arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Medivir

                            Sweden arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fostroxacitabine Bralpamide,Lenvatinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Medivir Reports Promising Interim Data, Including a First Complete Response in Phase 1B/2A HCC Study with Fost...

                            Details : MIV-818 (fostroxacitabine bralpamide) is an orally active troxacitabine-based nucleotide prodrug, which is investigated in with fostrox in combination with Lenvima for the treatment of primary liver cancer.

                            Brand Name : MIV-818

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 04, 2023

                            Lead Product(s) : Fostroxacitabine Bralpamide,Lenvatinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Medivir

                            Sweden arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Medivir

                            Sweden arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fostroxacitabine Bralpamide,Lenvatinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Promising Tumor Control for Fostrox in Combination with Lenvima in Ongoing Phase 2a Study in HCC, 15th Patient...

                            Details : MIV-818 (fostroxacitabine bralpamide) is an orally active troxacitabine-based nucleotide prodrug, which is investigated for the treatment of primary liver cancer.

                            Brand Name : MIV-818

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 14, 2023

                            Lead Product(s) : Fostroxacitabine Bralpamide,Lenvatinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Medivir

                            Sweden arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Medivir

                            Sweden arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fostroxacitabine Bralpamide,Lenvatinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Medivir's Patent Application for Fostrox Approved in China

                            Details : MIV-818 (fostroxacitabine bralpamide) is an orally active troxacitabine-based nucleotide prodrug, which is investigated for the treatment of primary liver cancer.

                            Brand Name : MIV-818

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 19, 2023

                            Lead Product(s) : Fostroxacitabine Bralpamide,Lenvatinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Medivir

                            Sweden arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Medivir

                            Sweden arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fostroxacitabine Bralpamide,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            First Patient Dosed in The Phase 2a Part of Medivir's Study with Fostrox in Combination with Lenvima®

                            Details : MIV-818 (fostroxacitabine bralpamide) is an orally active troxacitabine-based nucleotide prodrug. Its active metabolite troxacitabine triphosphate (TRX-TP) is then incorporated into rapidly dividing cancer cell's DNA, thereby causing DNA damage and cance...

                            Brand Name : MIV-818

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 14, 2023

                            Lead Product(s) : Fostroxacitabine Bralpamide,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Medivir

                            Sweden arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Medivir

                            Sweden arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fostroxacitabine Bralpamide,Lenvatinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Medivir Has Determined the Recommended Phase 2 Dose for Fostrox in Combination with Lenvima In HCC

                            Details : MIV-818 (fostroxacitabine bralpamide) is an orally active troxacitabine-based nucleotide prodrug. Its active metabolite troxacitabine triphosphate (TRX-TP) is then incorporated into rapidly dividing cancer cell's DNA, thereby causing DNA damage and cance...

                            Brand Name : MIV-818

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            February 20, 2023

                            Lead Product(s) : Fostroxacitabine Bralpamide,Lenvatinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth